Kybella ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04730583 (ClinicalTrials.gov) | May 2021 | 12/1/2021 | Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | Cutaneous Neurofibroma | Drug: Kybella;Device: 980nm laser;Device: 755nm Alexandrite Laser;Device: Radiofrequency | Massachusetts General Hospital | Johns Hopkins University | Not yet recruiting | 18 Years | 85 Years | All | 20 | Phase 1 | NULL |